EDITORIAL

Putting an End to the Guesswork

Assays that measure the susceptibility of a particular viral isolate to particular antiretroviral agents help clinicians devise successful successor regimens for patients who are failing therapy
WILLIAM G. POWDERLY M.D., EDITOR-IN-CHIEF

---

OPTIMAL MEDICAL MANAGEMENT

Entering the Era of Truly Individualized Antiretroviral Therapy

By combining resistance testing with drug-level monitoring, providers will be able to individualize therapy to a degree never previously possible
ANDREW D. LUBER, PHARM.D., and W. DAVID HARDY, M.D.

&

Clinical Considerations in Therapeutic Drug Monitoring

---

NEWSLINE

Newsline...Newsline...Newsline...

Update: Subcutaneous interleukin-2: Investigators observe dose-related increases in CD4 counts -- without increases in HIV RNA . . . Update: Treatment of lipodystrophy: Metformin reduces insulin resistance and visceral fat deposits . . . Scrub typhus and HIV co-infection: Does O. tsugamushi inhibit syncytia formation in seropositive patients?

---

PULLOUT

Trekking with AIDS, Part 3: A Special Report

An advocate for people living with AIDS proves that HIV infection is no impediment to completing this country's oldest and most famous wilderness trail
DAWN AVERITT

---

CASE MANAGEMENT

Michael T., a Longterm Survivor Who Is Failing His Fifth Salvage Regimen

Phenotype assay results -- reproduced here -- suggest a therapeutic option for a patient who has developed high-level resistance to two classes of antiretroviral agents
ANDREW D. LUBER, PHARM.D.